Initial clinical studies that dampen IL-1β signaling have shown promise in controlling diabetes but detailed evidence to support use of IL-1 neutralizing antibodies in diabetic patients has thus far not yielded successful results. This evidence concerns the gene IL1A and diabetes mellitus.